Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.

Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B.

Sci Transl Med. 2018 Sep 12;10(458). pii: eaas9563. doi: 10.1126/scitranslmed.aas9563.


Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, Hudecek M.

Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5. No abstract available.


A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.

O'Farrell AC, Evans R, Silvola JM, Miller IS, Conroy E, Hector S, Cary M, Murray DW, Jarzabek MA, Maratha A, Alamanou M, Udupi GM, Shiels L, Pallaud C, Saraste A, Liljenbäck H, Jauhiainen M, Oikonen V, Ducret A, Cutler P, McAuliffe FM, Rousseau JA, Lecomte R, Gascon S, Arany Z, Ky B, Force T, Knuuti J, Gallagher WM, Roivainen A, Byrne AT.

PLoS One. 2017 Jan 27;12(1):e0169964. doi: 10.1371/journal.pone.0169964. eCollection 2017.


The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.

Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR.

J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7.


Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R.

Lancet Oncol. 2015 Jun;16(6):716-28. doi: 10.1016/S1470-2045(15)70100-2. Epub 2015 May 14.


Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.

Pallaud C, Reck M, Juhasz E, Szima B, Yu CJ, Burdaeva O, Orlov S, Hilton M, Archer V, Mok T.

Lung Cancer. 2014 Oct;86(1):67-72. doi: 10.1016/j.lungcan.2014.07.019. Epub 2014 Aug 2.


Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.

de Haas S, Delmar P, Bansal AT, Moisse M, Miles DW, Leighl N, Escudier B, Van Cutsem E, Carmeliet P, Scherer SJ, Pallaud C, Lambrechts D.

Angiogenesis. 2014 Oct;17(4):909-20. doi: 10.1007/s10456-014-9438-1. Epub 2014 Jul 11.


A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).

Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V, Hilton M, Delmar P, Pallaud C, Reck M.

J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160.


Genetic markers of bevacizumab-induced hypertension.

Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C.

Angiogenesis. 2014 Jul;17(3):685-94. doi: 10.1007/s10456-014-9424-7. Epub 2014 Feb 21.


Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R.

Lancet Oncol. 2013 Sep;14(10):933-42. doi: 10.1016/S1470-2045(13)70335-8. Epub 2013 Aug 7.


AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.

J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8.


Genetic influences on lipid metabolism trait variability within the Stanislas Cohort.

Pallaud C, Gueguen R, Sass C, Grow M, Cheng S, Siest G, Visvikis S.

J Lipid Res. 2001 Nov;42(11):1879-90.


[Association between E-selectin Leu554Phe polymorphism and blood pressure in the Stanislas cohort].

Sass C, Pallaud C, Zannad F, Visvikis S.

Arch Mal Coeur Vaiss. 2001 Aug;94(8):855-8. French.


[APOC3, CETP, beta-fibrinogen and MTHFR are genetic determinants of carotid intim-media thickness (Stanislas cohort)].

Pallaud C, Sass C, Zannad F, Siest G, Visvikis S.

Arch Mal Coeur Vaiss. 2001 Aug;94(8):851-4. French.


Sample size calculations for classical association and TDT-type methods using family data.

Tregouet DA, Pallaud C, Sass C, Visvikis S, Tiret L.

Ann Hum Genet. 2001 May;65(Pt 3):293-312. doi: 10.1017/S0003480001008661.


APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort).

Pallaud C, Sass C, Zannad F, Siest G, Visvikis S.

Clin Genet. 2001 May;59(5):316-24.


Candidate gene polymorphisms in cardiovascular disease: a comparative study of frequencies between a French and an Italian population.

Pallaud C, Stranieri C, Sass C, Siest G, Pignatti F, Visvikis S.

Clin Chem Lab Med. 2001 Feb;39(2):146-54.


Familial studies on the genetics of cardiovascular diseases: the Stanislas cohort.

Visvikis S, Sass C, Pallaud C, Grow MA, Zannad F, Siest G, Erlich HA, Cheng S.

Clin Chem Lab Med. 2000 Sep;38(9):827-32. Erratum in: Clin Chem Lab Med 2000 Dec;38(12):1318.


Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort.

Sass C, Pallaud C, Zannad F, Visvikis S.

Hum Genet. 2000 Jul;107(1):58-61.


A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, Kane JP.

Genome Res. 1999 Oct;9(10):936-49.


Multilocus approach to cardiovascular risk.

Pallaud C, Maurice M, Cheng S, Grow M, Aguillon D, Sass C, Siest G, Visvikis S.

Scand J Clin Lab Invest Suppl. 1999;230:168-76.


A multilocus genotyping assay for cardiovascular disease.

Cheng S, Pallaud C, Grow MA, Scharf SJ, Erlich HA, Klitz W, Pullinger CR, Malloy MJ, Kane JP, Siest G, Visvikis S.

Clin Chem Lab Med. 1998 Aug;36(8):561-6.


Supplemental Content

Loading ...
Support Center